Close Menu
  • About
  • Products
    • Find Solutions
    • Technical Q&A
    • Novelty Search
    • Feasibility Analysis Assistant
    • Material Scout
    • Pharma Insights Advisor
    • More AI Agents For Innovation
  • IP
  • Machinery
  • Material
  • Life Science
Facebook YouTube LinkedIn
Eureka BlogEureka Blog
  • About
  • Products
    • Find Solutions
    • Technical Q&A
    • Novelty Search
    • Feasibility Analysis Assistant
    • Material Scout
    • Pharma Insights Advisor
    • More AI Agents For Innovation
  • IP
  • Machinery
  • Material
  • Life Science
Facebook YouTube LinkedIn
Patsnap eureka →
Eureka BlogEureka Blog
Patsnap eureka →
Home»Life Science»Autoimmune Diseases — Global Competitive Landscape Report 2026

Autoimmune Diseases — Global Competitive Landscape Report 2026

May 14, 202612 Mins Read
Share
Facebook Twitter LinkedIn Email

Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary

Moreover, autoimmune diseases collectively represent the second-largest therapeutic area after oncology, with 5,533 active drug programs across the disease cluster, 11,570 patent filings since January 2023, and over a million ongoing clinical trials when aggregated across the major indications (lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, IBD, myasthenia gravis, and others). Notably, 2025-2026 produced a transformational regulatory wave: Anbalcabtagene autoleucel and Puzolcabtagene Autoleucel — the first CAR-T therapies approved for autoimmune indications — alongside oral peptide IL-23 (Icotrokinra), BTK inhibitors for multiple sclerosis (Tolebrutinib, Remibrutinib), APRIL antagonist for IgA nephropathy (Sibeprenlimab), and complement inhibitors (Narsoplimab).

Specifically, the late-stage competitive frontier is segmenting into four strategic lanes: (1) cytokine-targeted biologics dominated by AbbVie’s Skyrizi/Rinvoq, Janssen’s Tremfya/Stelara/Icotrokinra, and Sanofi’s Dupixent across multiple indications; (2) BTK inhibitors led by Sanofi’s Tolebrutinib and Novartis’s Remibrutinib establishing a new oral mechanism for MS, MG, and chronic spontaneous urticaria; (3) CAR-T cell therapy reframing severe autoimmune disease as a curative-intent indication; and (4) emerging modalities including molecular glues, hypoimmune cell therapy (Sana), and retroelement-targeting platforms (Rome Therapeutics).

However, the strategic outlook is increasingly defined by mechanism diversification rather than incremental cytokine blockade. As a result, B-cell-depleting CAR-T, BTK, and APRIL antagonists represent the most active growth vectors. Furthermore, Chinese players including Hengrui, Akeso, and emerging biotech filers have dramatically increased patent activity, signaling that the next wave of autoimmune competition will increasingly originate from Asian pipelines.


Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.

Arena Overview

Pipeline by Modality

Across the 200+ sampled autoimmune programs, small molecules dominate with 105 entries (oral BTK, JAK, TYK2, S1P, PDE4 modulators), followed by 47 monoclonal antibodies, 5 autologous CAR-T programs, 5 synthetic peptides, 4 bispecific T-cell engagers, 4 Fc fusion proteins, 3 cyclic peptides, 3 non-degrading molecular glues, 2 Fc fragments, and 2 fecal microbiota transplantation programs. Notably, the rise of CAR-T (5 programs, 2 already approved in 2025-2026) and BiTEs (4 programs) signals that hematology cell-therapy modalities are migrating into severe autoimmune disease. Moreover, the molecular glue and Fc-fragment entries indicate that next-generation oral biologics — bridging small molecules and antibodies — are entering preclinical development.

Patent Filing Activity

However, patent activity since 2023 reflects intense innovation across modality classes. Specifically, Jiangsu Hengrui Medicine and Shanghai Hengrui Pharm each lead with 7 filings (14 combined under the Hengrui umbrella), followed by Rome Therapeutics at 4, Biogen and Sitryx Therapeutics at 3 each, then Shanghai Haiyan Pharma Tech, Yangtze River, Hainan Simcere, Calico Life Sci, AbbVie, BeneThera Beijing, and Bristol Myers Squibb each at 2. Importantly, the assignee mix combines big pharma (Biogen, AbbVie, BMS), Chinese platforms (Hengrui, Yangtze, Simcere, BeneThera), and novel-mechanism specialists (Rome Therapeutics for retroelement biology, Sitryx for immunometabolism, Calico for aging-related immunity) — a structural signal that autoimmune diseases will see continued mechanistic experimentation through 2027.

Player Summary Table

PlayerRegionTierLead ProductsKey Evidence
AbbVieUSTier 1 — LeaderSkyrizi, Rinvoq, Humira biosimilarsMulti-indication autoimmune leader
Janssen (J&J)US/BelgiumTier 1 — LeaderStelara, Tremfya, IcotrokinraIL-23 portfolio across PsO/PsA/IBD
SanofiFranceTier 1 — LeaderDupixent, TolebrutinibAtopic / asthma + MS BTK
Roche / GenentechSwitzerland/USTier 1 — LeaderOcrelizumab, Rituximab biosimilarsMS / RA B-cell depletion
NovartisSwitzerlandTier 1 — LeaderCosentyx, RemibrutinibIL-17 + BTK
Eli LillyUSTier 1 — LeaderTaltz, Mirikizumab, OlumiantMulti-indication immunology
BiogenUSTier 2 — ActiveMS portfolio, autoimmune pipeline3 patents 2023+
Bristol Myers SquibbUSTier 2 — ActiveSotyktu, ZeposiaOral TYK2 + S1P
UCBBelgiumTier 2 — ActiveBimzelxDual IL-17A/F
Hengrui (Jiangsu + Shanghai)ChinaTier 2 — ActiveIvarmacitinib, Jaktinib + multiple oral mAbs14 patents 2023+
AkesoChinaTier 2 — ActiveEbdarokimab + multiple bispecificsNMPA approvals across indications
Sana BiotechnologyUSTier 3 — EmergingHypoimmune CD19 / CD38 CAR-T2 patents 2023+; lupus and MS programs
Rome TherapeuticsUSTier 3 — EmergingRetroelement-targeted molecules4 patents 2023+; novel mechanism
Sitryx TherapeuticsUKTier 3 — EmergingImmunometabolism modulators3 patents 2023+
Calico Life SciencesUSTier 3 — EmergingAging-related immune modulators2 patents 2023+
Cabaletta BioUSTier 3 — EmergingCABA-201 CAR-TAutoimmune CAR-T platform

Generate Competitive Landscape Reports Like This — in Minutes

Powered by Eureka LS AI

  • ✔ Analyze patents, literature, and pipelines together
  • ✔ Extract molecule & SAR data automatically
  • ✔ Compare competitors and identify key assets
  • ✔ Get structured reports instantly
Start Free (Basic Plan)

Route Differentiation Analysis

RouteTier 1 LeadersTier 2 ActiveTier 3 EmergingStrategic Position
Cytokine-targeted mAb (IL-17, IL-23, IL-4/13)AbbVie, Janssen, Sanofi, Lilly, Novartis, UCBAkeso, HengruiMultiple biosimilarsSaturated — biosimilar transition
BTK inhibitor (oral)Sanofi (Tolebrutinib), Novartis (Remibrutinib)Multiple second-gen programsSeveral preclinicalDifferentiated — fast-growing
JAK / TYK2 oral inhibitorAbbVie (Upadacitinib), BMS (Deucravacitinib)Pfizer, Hengrui, ReistoneMultiple Chinese filersActive — black-box-warning constrained
S1P modulatorPfizer (Etrasimod), BMS (Ozanimod)Multiple second-gen programsSeveral preclinicalDifferentiated — third oral mechanism
Autologous CAR-T (B-cell depletion)—Cabaletta, Anbalcabtagene, PuzolcabtageneMultiple academic / ChineseDifferentiated — curative intent
Allogeneic / hypoimmune CAR-T—Sana BiotechnologyMultiple platformsEmerging — high reward
FcRn antagonistargenx (Efgartigimod), UCB (Rozanolixizumab)Multiple follow-onsMultiple Chinese filersActive — myasthenia and IgG-mediated AI
APRIL / BAFF antagonistSibeprenlimabMultiple second-gen programsSeveral preclinicalEmerging — IgA nephropathy
Retroelement / immunometabolism / molecular glue—Rome Therapeutics, Sitryx, CalicoMultiple platform companiesEmerging — novel-mechanism experimentation

Route Concentration Observations

  1. Notably, BTK inhibitors have emerged as the most strategically active route in 2025-2026, with two FDA approvals (Tolebrutinib for MS, Remibrutinib for chronic urticaria) and broad indication expansion.
  2. Moreover, autoimmune CAR-T has crossed the credibility threshold with two NMPA approvals (Anbalcabtagene autoleucel, Puzolcabtagene autoleucel), though Western regulatory pathways are still being established.
  3. However, FcRn antagonism (Efgartigimod, Rozanolixizumab) has expanded faster than expected, capturing IgG-mediated autoimmune indications including myasthenia gravis, ITP, and pemphigus.
  4. In addition, novel-mechanism platforms — retroelement biology (Rome), immunometabolism (Sitryx), aging-related immune modulators (Calico) — represent the long-tail experimentation that could reframe autoimmunity by 2030.

Top Player Deep Dives

AbbVie (Skyrizi + Rinvoq)

Primary route: In addition, anti-IL-23p19 mAb (Skyrizi) plus oral selective JAK1 inhibitor (Rinvoq), spanning psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis. Specifically, AbbVie has the broadest multi-indication immunology franchise.

Key pipeline: As a result, skyrizi and Rinvoq remain core; AbbVie also has 2 patents 2023+ across novel autoimmune mechanisms. Moreover, Humira biosimilar revenue continues to support continued investment in the pipeline.

Differentiation: Specifically, multi-indication labels and dual-modality positioning (biologic + oral) provide AbbVie with the largest commercial scale of any single immunology player. As a result, AbbVie is the single most commercially important autoimmune pharma globally.

Recent BD: Meanwhile, abbVie continues to invest internally in immunology; no major outbound BD recently.

Trajectory: In contrast, skyrizi and Rinvoq remain on track to be major franchise contributors. Consequently, lifecycle strategies focus on label expansion and combination approaches.

Key risk: Similarly, biosimilar entry post-LOE in late 2030s; near-term threat from oral peptide alternatives like Icotrokinra capturing convenience-driven segments.

Sanofi (Dupixent + Tolebrutinib)

Primary route: Furthermore, anti-IL-4Rα (Dupixent) for atopic dermatitis, asthma, EoE, prurigo nodularis, and chronic rhinosinusitis with nasal polyps; oral BTK inhibitor (Tolebrutinib) for multiple sclerosis. Specifically, Sanofi spans Th2-driven and B-cell-driven autoimmunity.

Key pipeline: Additionally, dupixent expands across IL-4/13-driven indications; Tolebrutinib received FDA approval in August 2025 for relapsing MS. Moreover, Sanofi has emerging anti-CD40L and other autoimmune programs.

Differentiation: Importantly, dupixent’s Th2-pathway breadth provides multi-indication revenue depth; Tolebrutinib’s CNS-penetrant BTK profile is uniquely positioned for MS. Furthermore, Sanofi has positioned the BTK molecule for both relapsing and progressive MS.

Recent BD: Overall, tolebrutinib was acquired through Principia Biopharma in 2020 ($3.7B); Dupixent was developed under the Regeneron alliance.

Trajectory: Indeed, dupixent remains a multi-billion franchise with continued indication expansion; Tolebrutinib launch dynamics in MS will be closely watched in 2026-2027.

Key risk: Consequently, dupixent biosimilar erosion post-LOE; Tolebrutinib hepatotoxicity signal that delayed earlier US approval may constrain prescribing.

Sana Biotechnology / Cabaletta (Autoimmune CAR-T)

Primary route: Therefore, allogeneic hypoimmune CAR-T (Sana SC-DARIC38) and autologous CD19 CAR-T (Cabaletta CABA-201) for severe autoimmune diseases including lupus, myositis, and systemic sclerosis. Specifically, B-cell depletion via CAR-T provides curative-intent therapy for refractory autoimmune disease.

Key pipeline: In particular, sana’s hypoimmune platform extends to CD38 and CD19; Cabaletta’s CABA-201 is in Phase 1/2 for multiple autoimmune indications. Moreover, multiple Chinese players have CAR-T autoimmune programs in development.

Differentiation: Likewise, curative-intent CAR-T positioning could transform refractory autoimmune disease economics by enabling one-time treatment instead of chronic biologics. Furthermore, Sana’s hypoimmune approach could eliminate lymphodepletion and enable ambulatory CAR-T administration.

Recent BD: Thus, multiple CAR-T autoimmune deals are in early-stage discussions; specific terms are not yet disclosed.

Trajectory: For example, phase 1/2 readouts in 2025-2026 will determine whether autoimmune CAR-T moves from exceptional case reports to scalable therapy. As a result, this is one of the highest-reward, highest-risk autoimmune routes.

Key risk: At the same time, lymphodepletion safety, CAR-T persistence, and operational complexity all constrain real-world rollout in autoimmune populations.

Hengrui & Akeso (Chinese Multi-Mechanism Players)

Primary route: By contrast, hengrui leads with oral JAK family (Ivarmacitinib, Jaktinib) plus multiple antibody and small-molecule programs across autoimmune indications. Specifically, Akeso has multiple IL-17/IL-23 mAb approvals and developing bispecifics.

Key pipeline: Of course, hengrui has 14 autoimmune-related patents 2023+ across two corporate entities; Akeso has multiple NMPA-approved IL-17/IL-23 mAbs. Moreover, both companies are advancing oral peptide and bispecific programs.

Differentiation: Finally, pricing-led positioning and rapid NMPA approvals capture domestic Chinese share at scale. Furthermore, Chinese-developed oral chemistry has established differentiated cost-of-goods relative to Western mAbs.

Recent BD: Notably, multiple ex-China licensing discussions ongoing across both companies; Hengrui has executed several recent ex-China oncology deals that may extend into autoimmune indications.

Trajectory: Moreover, chinese players will continue to dominate domestic autoimmune share. As a result, the most credible global expansion stories will come via emerging-market licensing rather than US/EU launches.

Key risk: However, limited cardiovascular and long-term safety data versus established Western mAbs may constrain reimbursement in payer-driven markets.

Rome Therapeutics / Sitryx / Calico (Novel-Mechanism Platforms)

Primary route: In addition, rome Therapeutics targets transposable element / retroelement biology that drives interferon signaling in autoimmune disease; Sitryx focuses on immunometabolism modulators; Calico explores aging-related immune dysregulation. Specifically, all three target mechanisms outside the conventional cytokine and B-cell axes.

Key pipeline: As a result, rome has 4 patents 2023+ and multiple discovery-stage programs; Sitryx has 3 patents 2023+; Calico has 2 patents 2023+. Moreover, all three companies maintain academic and pharma partnerships.

Differentiation: Specifically, novel-mechanism platforms target the underlying drivers of autoimmunity rather than downstream cytokine effects, potentially providing disease-modifying or curative therapies. Furthermore, the platforms are mechanism-extensible across multiple indications.

Recent BD: Meanwhile, rome has pharma partnerships in multiple stages; Sitryx and Calico maintain VC and pharma collaborations.

Trajectory: In contrast, discovery to early clinical-stage. Validation depends on Phase 1/2 readouts of lead programs in 2026-2028.

Key risk: Similarly, mechanism-to-clinical translation gaps remain wide for novel autoimmune mechanisms; preclinical efficacy does not guarantee clinical relevance.


BD Deals & Strategic Moves

Deal Timeline

DateDealPartiesTypeSignificance
2026-04Anbalcabtagene autoleucel approvalChinese sponsorRegulatoryFirst CAR-T approval for autoimmune disease
2025-11Puzolcabtagene autoleucel approvalChinese sponsorRegulatorySecond autoimmune CAR-T approval
2025-08Tolebrutinib FDA approvalSanofiRegulatoryFirst BTK inhibitor for relapsing MS
2025-09Remibrutinib FDA approvalNovartisRegulatoryBTK for chronic spontaneous urticaria
2025-11Sibeprenlimab IgAN approvalVisterra/OtsukaRegulatoryAPRIL antagonist for IgA nephropathy
2024-Q3Sana hypoimmune CAR-T autoimmune trialsSana BiotechnologyTrialHypoimmune CD19 CAR-T in lupus enrollment
2023-Q4Cabaletta CABA-201 advancementCabaletta BioTrialMultiple Phase 1/2 autoimmune cohorts

Strategic Pattern

Notably, the BD landscape signals premium valuations for novel autoimmune mechanisms — with BTK, FcRn, APRIL, and CAR-T attracting the largest deals. Furthermore, autoimmune CAR-T’s Chinese-led approvals validate the modality and create pressure for Western regulatory engagement. However, traditional cytokine-targeted licensing has slowed, suggesting the field has internalized the maturity of the mAb route and now invests in mechanism diversification.


Unmet Needs & White Spaces

Opportunity Matrix

Unmet NeedCurrent ApproachesGapWhite Space
Refractory autoimmune disease (curative)Autologous & allogeneic CAR-TLimited approved options outside ChinaHypoimmune CAR-T, in vivo CAR-T, gene therapy
Progressive multiple sclerosisTolebrutinib, ocrelizumabLimited disease-modifying therapyCNS-penetrant BTK, microglial modulators
Pediatric autoimmune diseaseLimited pediatric labelsMost products restricted to adultsPediatric-specific dosing and formulations

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

  1. Notably, biosimilar entry of major IL-17, IL-23, TNF, and B-cell biologics from late 2020s will compress pricing across the entire injectable biologic class, eroding the franchise that has subsidized continued investment in autoimmune innovation.
  2. Moreover, oral biologic competition (Icotrokinra, Sotyktu, BTK inhibitors) is reshaping the moderate-to-severe segment, potentially eroding mAb commercial positioning faster than current trajectories imply.
  3. However, autoimmune CAR-T faces lymphodepletion safety, persistence, and operational scale challenges that may limit broad adoption outside specialist centers.
  4. In addition, payer pressure on multi-billion biologic spending may force reimbursement restrictions favoring lower-cost oral and biosimilar alternatives.

Strategic Outlook

Overall, autoimmune diseases have crossed from a competitive innovation phase anchored by cytokine biologics into a multi-modality phase including BTK, CAR-T, FcRn, APRIL antagonism, and emerging novel-mechanism platforms. Furthermore, the next 24 to 36 months will be defined by Tolebrutinib and Remibrutinib launch dynamics, autoimmune CAR-T regulatory engagement in Western markets, and the maturation of platform-level competition between Sana, Cabaletta, Rome, Sitryx, and Calico. Meanwhile, Chinese players will continue to dominate the bispecific and oral chemistry routes, with the most credible global partnerships likely to come through ex-China licensing.

If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.

Turn Complex Data into Decision-Ready Insights

Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.

  • ✔ Domain-specific research Q&A
  • ✔ Patent & literature analysis (2 files per upload)
  • ✔ Lead compound analysis with SAR extraction (5 runs)
  • ✔ 2 AI-powered Pulse briefs for early signals
Try It Free →
Try Eureka LS free
Autoimmune Diseases biotech analysis competitive landscape drug discovery drug pipeline pharma market
Share. Facebook Twitter LinkedIn Email
Previous ArticleInflammatory Bowel Diseases — Global Competitive Landscape Report 2026
Next Article 如何提高锂电池能量密度到260瓦时/千克(Wh/kg)且体积没有变大

Related Posts

How to Convert an SDF File to CSV and Keep the Structures Visible

October 23, 2026

What Is a Linker in a Drug Molecule?

October 23, 2026

What Is Canonical SMILES?

October 23, 2026

Extracting Compounds from Molecular Glue Degrader Patents

October 23, 2026

Extracting Compounds from BTK Inhibitor Patents

October 23, 2026

Why Chemical Patents Keep Their Structures in Images

October 23, 2026

Comments are closed.

Patsnap Eureka Life Sciences

Get free access today!

Eureka LS helps you rank optimal molecules (PCC), analyze complex modalities (like ADC & CAR-T), and conduct traceable due diligence, powered by comprehensive global patent and bio-sequence data.

⚡️ Get started →
Table of Contents
  • Executive Summary
  • Arena Overview
  • Route Differentiation Analysis
  • Top Player Deep Dives
  • BD Deals & Strategic Moves
  • Unmet Needs & White Spaces
  • Risks and Strategic Outlook for 2026 and Beyond
About Us
About Us

Eureka harnesses unparalleled innovation data and effortlessly delivers breakthrough ideas for your toughest technical challenges. Eliminate complexity, achieve more.

Facebook YouTube LinkedIn
Latest Hotspot

Elementor #38874

August 7, 2026

Sheet-Metal Fastening: Pick the Process Before Cost and Reliability Slip

July 31, 2026

Learn Cost Reduction from Musk: The “Idiot Index”

July 31, 2026
tech newsletter

35 Breakthroughs in Magnetic Resonance Imaging – Product Components

July 1, 2024

27 Breakthroughs in Magnetic Resonance Imaging – Categories

July 1, 2024

40+ Breakthroughs in Magnetic Resonance Imaging – Typical Technologies

July 1, 2024
© 2026 Patsnap Eureka. Powered by Patsnap Eureka.

Type above and press Enter to search. Press Esc to cancel.